MLAB Form 4: Director Tripeny Vesting 1,404 Shares, 2,784 RSUs Granted

Q: What did Mesa Laboratories (MLAB) director Tony Tripeny report on Form 4?

The filing reports 1,404 shares acquired on 08/15/2025 from RSU vesting and a grant of 2,784 RSUs that vest on 08/15/2026 , leaving 4,083 shares beneficially owned.

Q: When do the newly granted RSUs reported by the MLAB director vest?

The newly granted 2,784 RSUs are stated to vest on 08/15/2026 .

Q: Who signed the Form 4 for Tony Tripeny and when was it signed?

The Form 4 was signed under power of attorney by John Sakys on 08/18/2025 .

[Form 4] Mesa Laboratories Inc Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tony Tripeny, a director of Mesa Laboratories, reported transactions on 08/15/2025 that changed his beneficial ownership in the company's common stock. 1,404 shares were acquired upon vesting of Restricted Stock Units (RSUs) (price reported as $0) and 2,784 RSUs were granted that vest on 08/15/2026. After these transactions, he beneficially owns 4,083 shares. The Form 4 was filed with an 08/18/2025 signature executed by a power of attorney. All items reported relate to non-derivative shares and RSU awards described in the filing.

Positive

Alignment with shareholders: RSU vesting and new RSU awards align director compensation with long-term share performance
Clear reporting: Transactions and vesting schedule are explicitly disclosed, showing compliance with Section 16 reporting obligations
Ownership increase: Beneficial ownership increased to 4,083 shares following vesting

Negative

None.

Insights

TL;DR: Director received routine RSU vesting and additional RSU award, modestly increasing reported ownership.

The reported activity is consistent with standard equity compensation: 1,404 RSUs vested and were converted to common shares at no cash price, and 2,784 RSUs were granted that vest one year later. The overall stake of 4,083 shares is small relative to typical institutional holdings and does not indicate a material change in control or significant insider accumulation. This is a routine disclosure that primarily reflects compensation vesting schedules rather than a market-directed purchase.

TL;DR: Transaction appears to be routine director compensation vesting with standard reporting via Form 4.

The filing documents the vesting of RSUs and the grant of additional RSUs with a one-year vesting horizon, aligning the directors incentives with long-term shareholder value. The use of a power of attorney to sign the Form 4 is noted and acceptable under reporting rules. There are no departures, option exercises, or other governance actions disclosed that would suggest unusual insider behavior.

08/18/2025 - 01:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tripeny R Tony

(Last)

(First)

(Middle)

ONE RIVERFRONT PLAZA

(Street)

CORNING

14831

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/15/2025		M		1,404	A	$0	4,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units - 3	⁽¹⁾	08/15/2025		M			1,404	⁽²⁾	⁽³⁾	Common Stock	1,404	$0	0	D
Restricted Stock Units - 4	⁽¹⁾	08/15/2025		A		2,784		⁽⁴⁾	⁽³⁾	Common Stock	2,784	$0	2,784	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of the Issuer's common stock

2. RSUs that vested on August 15, 2025

3. Not Applicable

4. RSUs that vest on August 15, 2026

	John Sakys under Power of Attorney by Tony Tripeny	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Mesa Laboratories (MLAB) director Tony Tripeny report on Form 4?

The filing reports 1,404 shares acquired on 08/15/2025 from RSU vesting and a grant of 2,784 RSUs that vest on 08/15/2026, leaving 4,083 shares beneficially owned.

Were any shares purchased for cash in the reported transactions for MLAB?

No cash purchase was reported; the RSU vesting shows a price of $0 for the 1,404 shares acquired.

When do the newly granted RSUs reported by the MLAB director vest?

The newly granted 2,784 RSUs are stated to vest on 08/15/2026.

Who signed the Form 4 for Tony Tripeny and when was it signed?

The Form 4 was signed under power of attorney by John Sakys on 08/18/2025.

Does the Form 4 indicate any derivative transactions for MLAB?

Yes; the filing details RSU awards, which are derivative-like until settled, but the vested RSUs converted to 1,404 common shares and the outstanding RSUs total 2,784.

AG真人官方

[Form 4] Mesa Laboratories Inc Insider Trading Activity

Insights

FAQ

What did Mesa Laboratories (MLAB) director Tony Tripeny report on Form 4?

Were any shares purchased for cash in the reported transactions for MLAB?

When do the newly granted RSUs reported by the MLAB director vest?

Who signed the Form 4 for Tony Tripeny and when was it signed?

Does the Form 4 indicate any derivative transactions for MLAB?

NASDAQ:MLAB

MLAB Rankings

MLAB Latest News

MLAB Latest SEC Filings

MLAB Stock Data

AG真人官方

Trending News

[Form 4] Mesa Laboratories Inc Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

What did Mesa Laboratories (MLAB) director Tony Tripeny report on Form 4?

Were any shares purchased for cash in the reported transactions for MLAB?

When do the newly granted RSUs reported by the MLAB director vest?

Who signed the Form 4 for Tony Tripeny and when was it signed?

Does the Form 4 indicate any derivative transactions for MLAB?

NASDAQ:MLAB

MLAB Rankings

MLAB Latest News

MLAB Latest SEC Filings

MLAB Stock Data